ANBIO BIOTECHNOLOGY Financials
This page shows ANBIO BIOTECHNOLOGY (NNNN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
ANBIO BIOTECHNOLOGY has an operating margin of 24.4%, meaning the company retains $24 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is down from 29.2% the prior year.
ANBIO BIOTECHNOLOGY's revenue surged 21.9% year-over-year to $8.2M, reflecting rapid business expansion. This strong growth earns a score of 91/100.
ANBIO BIOTECHNOLOGY carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 10.71, ANBIO BIOTECHNOLOGY holds $10.71 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
ANBIO BIOTECHNOLOGY's ROE of 13.8% shows moderate profitability relative to equity, earning a score of 55/100. This is down from 15.2% the prior year.
ANBIO BIOTECHNOLOGY scores 390.78, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.1B) relative to total liabilities ($1.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
ANBIO BIOTECHNOLOGY passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, ANBIO BIOTECHNOLOGY generates $0.88 in operating cash flow ($2.1M OCF vs $2.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
ANBIO BIOTECHNOLOGY generated $8.2M in revenue in fiscal year 2024. This represents an increase of 21.9% from the prior year.
ANBIO BIOTECHNOLOGY reported $2.4M in net income in fiscal year 2024. This represents an increase of 5.3% from the prior year.
ANBIO BIOTECHNOLOGY earned $0.06 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 46.7% from the prior year.
ANBIO BIOTECHNOLOGY held $11.8M in cash against $0 in long-term debt as of fiscal year 2024.
ANBIO BIOTECHNOLOGY's gross margin was 71.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 21.8 percentage points from the prior year.
ANBIO BIOTECHNOLOGY's operating margin was 24.4% in fiscal year 2024, reflecting core business profitability. This is down 4.8 percentage points from the prior year.
ANBIO BIOTECHNOLOGY's net profit margin was 29.0% in fiscal year 2024, showing the share of revenue converted to profit. This is down 4.6 percentage points from the prior year.
ANBIO BIOTECHNOLOGY's ROE was 13.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 1.4 percentage points from the prior year.
ANBIO BIOTECHNOLOGY invested $454K in research and development in fiscal year 2024. This represents an increase of 237.2% from the prior year.
NNNN Income Statement
| Metric | Q4'24 | Q4'23 |
|---|---|---|
| Revenue | N/A | N/A |
| Cost of Revenue | N/A | N/A |
| Gross Profit | N/A | N/A |
| R&D Expenses | N/A | N/A |
| SG&A Expenses | N/A | N/A |
| Operating Income | N/A | N/A |
| Interest Expense | N/A | N/A |
| Income Tax | N/A | N/A |
| Net Income | N/A | N/A |
| EPS (Diluted) | N/A | N/A |
NNNN Balance Sheet
| Metric | Q4'24 | Q4'23 |
|---|---|---|
| Total Assets | $18.9M+19.7% | $15.8M |
| Current Assets | $18.5M+17.7% | $15.7M |
| Cash & Equivalents | $11.8M+21.4% | $9.7M |
| Inventory | N/A | N/A |
| Accounts Receivable | $1.1M-43.5% | $1.9M |
| Goodwill | N/A | N/A |
| Total Liabilities | $1.7M+74.2% | $993K |
| Current Liabilities | $1.7M+74.2% | $993K |
| Long-Term Debt | N/A | N/A |
| Total Equity | $17.2M+16.0% | $14.8M |
| Retained Earnings | $17.2M+16.0% | $14.8M |
NNNN Cash Flow Statement
| Metric | Q4'24 | Q4'23 |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Investing Cash Flow | N/A | N/A |
| Financing Cash Flow | N/A | N/A |
| Dividends Paid | N/A | N/A |
| Share Buybacks | N/A | N/A |
NNNN Financial Ratios
| Metric | Q4'24 | Q4'23 |
|---|---|---|
| Gross Margin | N/A | N/A |
| Operating Margin | N/A | N/A |
| Net Margin | N/A | N/A |
| Return on Equity | N/A | N/A |
| Return on Assets | N/A | N/A |
| Current Ratio | 10.71-5.1 | 15.86 |
| Debt-to-Equity | 0.10+0.0 | 0.07 |
| FCF Margin | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is ANBIO BIOTECHNOLOGY's annual revenue?
ANBIO BIOTECHNOLOGY (NNNN) reported $8.2M in total revenue for fiscal year 2024. This represents a 21.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ANBIO BIOTECHNOLOGY's revenue growing?
ANBIO BIOTECHNOLOGY (NNNN) revenue grew by 21.9% year-over-year, from $6.7M to $8.2M in fiscal year 2024.
Is ANBIO BIOTECHNOLOGY profitable?
Yes, ANBIO BIOTECHNOLOGY (NNNN) reported a net income of $2.4M in fiscal year 2024, with a net profit margin of 29.0%.
What is ANBIO BIOTECHNOLOGY's earnings per share (EPS)?
ANBIO BIOTECHNOLOGY (NNNN) reported diluted earnings per share of $0.06 for fiscal year 2024. This represents a -46.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is ANBIO BIOTECHNOLOGY's gross margin?
ANBIO BIOTECHNOLOGY (NNNN) had a gross margin of 71.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is ANBIO BIOTECHNOLOGY's operating margin?
ANBIO BIOTECHNOLOGY (NNNN) had an operating margin of 24.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is ANBIO BIOTECHNOLOGY's net profit margin?
ANBIO BIOTECHNOLOGY (NNNN) had a net profit margin of 29.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is ANBIO BIOTECHNOLOGY's return on equity (ROE)?
ANBIO BIOTECHNOLOGY (NNNN) has a return on equity of 13.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is ANBIO BIOTECHNOLOGY's operating cash flow?
ANBIO BIOTECHNOLOGY (NNNN) generated $2.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are ANBIO BIOTECHNOLOGY's total assets?
ANBIO BIOTECHNOLOGY (NNNN) had $18.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does ANBIO BIOTECHNOLOGY spend on research and development?
ANBIO BIOTECHNOLOGY (NNNN) invested $454K in research and development during fiscal year 2024.
What is ANBIO BIOTECHNOLOGY's current ratio?
ANBIO BIOTECHNOLOGY (NNNN) had a current ratio of 10.71 as of fiscal year 2024, which is generally considered healthy.
What is ANBIO BIOTECHNOLOGY's debt-to-equity ratio?
ANBIO BIOTECHNOLOGY (NNNN) had a debt-to-equity ratio of 0.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ANBIO BIOTECHNOLOGY's return on assets (ROA)?
ANBIO BIOTECHNOLOGY (NNNN) had a return on assets of 12.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is ANBIO BIOTECHNOLOGY's Altman Z-Score?
ANBIO BIOTECHNOLOGY (NNNN) has an Altman Z-Score of 390.78, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ANBIO BIOTECHNOLOGY's Piotroski F-Score?
ANBIO BIOTECHNOLOGY (NNNN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ANBIO BIOTECHNOLOGY's earnings high quality?
ANBIO BIOTECHNOLOGY (NNNN) has an earnings quality ratio of 0.88x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is ANBIO BIOTECHNOLOGY?
ANBIO BIOTECHNOLOGY (NNNN) scores 89 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.